MBX Biosciences
MBX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +71.1% in FY2025
P. Kent Hawryluk is the CEO of MBX Biosciences and was paid $3.0M in FY2025 (Dec), up 34%.
Pay$100 in the stock at the end of FY24 → $171
Executives3
See all- 1P. Kent HawrylukPresident and Chief Executive OfficerFY2025
- 2Richard BartramFormer Chief Financial OfficerFY2025
- 3Salomon Azoulay, M.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMBX Biosciences paid its 3 named executives $6.0M in total in FY2025 (Dec). CEO P. Kent Hawryluk was paid $3.0M of that.
| Name | |||
|---|---|---|---|
| P. Kent HawrylukPresident and Chief Executive Officer | |||
| Richard BartramFormer Chief Financial Officer | |||
| Salomon Azoulay, M.D.Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for MBX Biosciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Edward T. MathersDirector · 5 yr on the boardIndependentNominating and Corporate Governance, Science and Medicine—Paid as an executive
- Patrick J. HeronDirector · 5 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance—Paid as an executive
- Laurie StelzerDirector · -1 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings4
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 17, 2025 | FY2024 |
